Novo Holdings completes Catalent acquisition for $16.5bn
by 
Novo Holdings, a global investment firm focused on life sciences, has completed its previously announced acquisition of Catalent. Under private ownership, Catalent benefits from Novo Holdings’ significant resources, and is well-positioned to deliver unparalleled outcomes for customers and patients they serve. The takeover also means that a related $11 billion transaction in which Novo Holdings’ subsidiary Novo Nordisk takes control of three of Catalent’s fill-and-finish facilities in Italy, Belgium, and the US has also made it over the line.
As a major pharma services company, Catalent enables its global pharma, biotech, and consumer health partners to optimize their own operations – starting with product development through to product launch and full life-cycle supply. The company aims to enhance its status as a global service provider for the pharmaceutical and biotechnology sectors while operating under private ownership. Catalent president and CEO Alessandro Maselli will continue to lead the company following the acquisition.
Novo Holdings CEO Kasim Kutay stated: “We are pleased to welcome Alessandro and the talented Catalent team to the Novo Holdings family.
“Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology and consumer health companies, and its mission is closely aligned with Novo Holdings’ purpose to invest for the benefit of people and the planet.”
Visit our upcoming pharma conferences – https://virtueinsight.com/upcoming-conferences/
